Asian Fund for Cancer Research Limited – AFCR shared a post on LinkedIn:
“At the AFCR–CityU Symposium on Precision and Digital Medicine at BIOHK2024, Professor Hai Yan of A*STAR shared how his team’s discovery of IDH1 and IDH2 mutations helped reshape the classification and diagnosis of glioma and contributed to the development of targeted therapies. From fundamental discovery to clinical application, his work demonstrates how molecular research can help advance precision oncology.
Looking ahead to BIOHK2026 this September, Asian Fund for Cancer Research Limited looks forward to supporting continued scientific exchange and cross-disciplinary collaboration across biotechnology, healthcare, and the life sciences.
Learn more about AFCR’s symposia at BIOHK.”
Other posts about AFCR on OncoDaily.